Veradermics CEO Reid Waldman is selected as a Forbes 30 Under 30 for 2024

Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)

Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts

Veradermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses